167 related articles for article (PubMed ID: 10992171)
1. CA 125 measurement and ultrasonography in borderline tumors of the ovary.
Gotlieb WH; Soriano D; Achiron R; Zalel Y; Davidson B; Kopolovic J; Novikov I; Ben-Baruch G
Am J Obstet Gynecol; 2000 Sep; 183(3):541-6. PubMed ID: 10992171
[TBL] [Abstract][Full Text] [Related]
2. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
3. Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non-invasive malignant serous ovarian tumors.
Moro F; Baima Poma C; Zannoni GF; Vidal Urbinati A; Pasciuto T; Ludovisi M; Moruzzi MC; Carinelli S; Franchi D; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2017 Dec; 50(6):788-799. PubMed ID: 28101917
[TBL] [Abstract][Full Text] [Related]
4. Management and outcome of borderline ovarian tumors incidentally discovered at or after laparoscopy.
Darai E; Teboul J; Fauconnier A; Scoazec JY; Benifla JL; Madelenat P
Acta Obstet Gynecol Scand; 1998 Apr; 77(4):451-7. PubMed ID: 9598957
[TBL] [Abstract][Full Text] [Related]
5. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
6. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
Saygili U; Uslu T; Erten O; Doğan E
Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
[TBL] [Abstract][Full Text] [Related]
7. Stage IA ovarian cancers: comparison of sonographic findings and histopathologic types between patients with normal and elevated serum cancer antigen 125 levels.
Hirai M; Hirai Y; Tsuchida T; Takada T; Iwase H; Utsugi K; Sugiyama Y; Takeshima N; Furuta R; Takizawa K
J Ultrasound Med; 2011 Jul; 30(7):943-52. PubMed ID: 21705727
[TBL] [Abstract][Full Text] [Related]
8. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors.
Zanetta G; Rota S; Lissoni A; Meni A; Brancatelli G; Buda A
Gynecol Oncol; 2001 Apr; 81(1):63-6. PubMed ID: 11277651
[TBL] [Abstract][Full Text] [Related]
9. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
10. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
[TBL] [Abstract][Full Text] [Related]
11. Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature.
Kolwijck E; Thomas CM; Bulten J; Massuger LF
Int J Gynecol Cancer; 2009 Nov; 19(8):1335-8. PubMed ID: 20009886
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis of ovarian tumors by sonography].
Wu ZY; Zhang GY; Du ZB
Zhonghua Fu Chan Ke Za Zhi; 1994 Feb; 29(2):100-2, 125. PubMed ID: 8033625
[TBL] [Abstract][Full Text] [Related]
13. The serum CA-125 concentration data assists in evaluating CT imaging information when used to differentiate borderline ovarian tumor from malignant epithelial ovarian tumors.
Shin JE; Choi HJ; Kim MH; Cho KS
Korean J Radiol; 2011; 12(4):456-62. PubMed ID: 21852906
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
15. Extraovarian cystadenomas: ultrasound and MR findings in 7 cases.
Ghossain MA; Braidy CG; Kanso HN; Farah K; Klein-Tomb L; Trak-Smayra V; Suidan JS; Elhage A; Atallah D; Abboud J
J Comput Assist Tomogr; 2005; 29(1):74-9. PubMed ID: 15665687
[TBL] [Abstract][Full Text] [Related]
16. [Profiling of serum tumor markers in patients with epithelial ovarian carcinoma].
Dong L; Li XP; Cui H; Wang JL; Wei LH; Zhao Y; Wang SJ; Wang Y; Sun XL; Liang XD; Li Y
Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):121-5. PubMed ID: 19570423
[TBL] [Abstract][Full Text] [Related]
17. The risk of malignancy index (RMI) in diagnosis of ovarian malignancy.
Moolthiya W; Yuenyao P
Asian Pac J Cancer Prev; 2009; 10(5):865-8. PubMed ID: 20162854
[TBL] [Abstract][Full Text] [Related]
18. Imaging in gynecological disease (11): clinical and ultrasound features of mucinous ovarian tumors.
Moro F; Zannoni GF; Arciuolo D; Pasciuto T; Amoroso S; Mascilini F; Mainenti S; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2017 Aug; 50(2):261-270. PubMed ID: 28782867
[TBL] [Abstract][Full Text] [Related]
19. Calcifications in mucinous and serous cystic ovarian tumors.
Okada S; Ohaki Y; Inoue K; Kawamura T; Hayashi T; Kato T; Kumazaki T
J Nippon Med Sch; 2005 Feb; 72(1):29-33. PubMed ID: 15834205
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of two groups of patients with serous and mucinous types of borderline ovarian tumors].
Makarewicz H; Emerich J; Olszewski J
Ginekol Pol; 2003 Jan; 74(1):24-31. PubMed ID: 12715434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
